These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12557436)

  • 1. [Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor].
    Zakrzewska I; Kozłowski L; Wojtukiewicz M
    Pol Merkur Lekarski; 2002 Oct; 13(76):302-4. PubMed ID: 12557436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.
    Romppanen J; Keskikuru R; Kataja V; Eskelinen M; Kosma VM; Savolainen K; Uusitupa M; Mononen I
    Br J Cancer; 1999 Mar; 79(9-10):1583-7. PubMed ID: 10188910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy].
    Zakrzewska I; Poznański J
    Przegl Lek; 2003; 60(1):18-20. PubMed ID: 12884640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of changes in levels of interleukin 6 and C reactive protein in patients with breast tumors].
    Zakrzewska I; Kozłowski L; Wojtukiewicz M
    Pol Merkur Lekarski; 2003 Aug; 15(86):115-7. PubMed ID: 14648971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients.
    Kozłowski L; Zakrzewska I; Tokajuk P; Wojtukiewicz MZ
    Rocz Akad Med Bialymst; 2003; 48():82-4. PubMed ID: 14737948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of plasma interleukin-6 and interleukin-8 in monitoring of patients with breast cancer].
    Zakrzewska I; Omyła J
    Pol Merkur Lekarski; 2005 Apr; 18(106):424-6. PubMed ID: 16161926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The levels of selected cytokines in patients with colorectal cancer--a preliminary report].
    Grotowski M; Piechota W
    Pol Merkur Lekarski; 2001 Oct; 11(64):327-9. PubMed ID: 11770312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MSA--a new sensitive tumor marker in breast carcinoma].
    Zahm DM; Greinke C; Nöschel H
    Zentralbl Gynakol; 1996; 118(12):659-64. PubMed ID: 9082702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma].
    Zakrzewska I; Poznański J
    Pol Merkur Lekarski; 2001 Sep; 11(63):210-3. PubMed ID: 11761812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
    Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
    Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of serum riboflavin carrier protein in breast cancer.
    Rao PN; Levine E; Myers MO; Prakash V; Watson J; Stolier A; Kopicko JJ; Kissinger P; Raj SG; Raj MH
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):985-90. PubMed ID: 10566553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of hepatocyte growth factor in patients with breast cancer.
    Sheen-Chen SM; Liu YW; Eng HL; Chou FF
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-G is a potential tumor marker in malignant ascites.
    Singer G; Rebmann V; Chen YC; Liu HT; Ali SZ; Reinsberg J; McMaster MT; Pfeiffer K; Chan DW; Wardelmann E; Grosse-Wilde H; Cheng CC; Kurman RJ; Shih IeM
    Clin Cancer Res; 2003 Oct; 9(12):4460-4. PubMed ID: 14555519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the BT-1 serum assay for breast cancer.
    Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
    Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma.
    Cheng KS; Tang HL; Chou FT; Chou JW; Hsu CH; Yu CJ; Kao ST; Li TC
    Hepatogastroenterology; 2009; 56(93):1105-10. PubMed ID: 19760951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
    Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pregnancy protein-1 in the serum of patients with diseases of the breast].
    Strache RR; Briese V; Szabo DG; Than GN; Kunze M; Richter D
    Zentralbl Gynakol; 1987; 109(5):274-9. PubMed ID: 3035827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.